NCT03535740 2025-07-31
ALTA-2
Takeda
Phase 2 Completed
Clinical Trials
4 trialsNCT03410108 2024-05-08
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 2 Completed
NCT02706626 2023-01-26
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Criterium, Inc.
Phase 2 Terminated
NCT02094573 2021-03-15
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Takeda
Phase 2 Completed